<DOC>
	<DOC>NCT00499200</DOC>
	<brief_summary>The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease (AD) subjects.</brief_summary>
	<brief_title>Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criteria: Men or women from 60 years of age at screening. Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12lead electrocardiogram (ECG). Exclusion criteria: History of drug abuse within 1 year before study day 1.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>